Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.

IF 5.6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Communications Pub Date : 2025-08-29 eCollection Date: 2025-09-01 DOI:10.1097/HC9.0000000000000801

Takeshi Hatanaka, Kei Shibuya, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Yuichi Koshiyama, Atsushi Naganuma, Yuhei Miyasaka, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Shinichiro Nakamura, Takashi Kumada, Tatsuya Ohno

{"title":"Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.","authors":"Takeshi Hatanaka, Kei Shibuya, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Yuichi Koshiyama, Atsushi Naganuma, Yuhei Miyasaka, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Shinichiro Nakamura, Takashi Kumada, Tatsuya Ohno","doi":"10.1097/HC9.0000000000000801","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.Methods: This retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.Results: The median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.Conclusions: CIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":"9 9","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HC9.0000000000000801","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study aimed to compare the clinical outcomes of carbon-ion radiotherapy (CIRT) to those of surgical resection (SR) in patients with HCC.

Methods: This retrospective study included 116 and 947 patients initially receiving CIRT and SR in Japanese institutions from September 2010 and June 2022. We used inverse probability of treatment weighting (IPTW) analysis to correct for imbalances in baseline patient characteristics between the 2 groups.

Results: The median observation period was 3.3 years (IQR: 1.4-5.8) in the SR group and 2.8 years (IQR: 1.6-4.5) in the CIRT group (p=0.2). Before IPTW analysis, the median recurrence-free survival (RFS) was 2.3 years in the SR group and 2.2 years in the CIRT group, with no statistical significance (p=0.3). After IPTW analysis, the median RFS was 2.5 years in the SR group and 2.3 years in the CIRT group, which remained statistically nonsignificant (p=0.9). The median overall survival (OS) was not reached in the SR group, while it was 7.4 years in the CIRT group. The SR group demonstrated better survival compared to the CIRT group (p=0.02). In the IPTW cohort, the median OS was not reached in the SR group, while it remained 7.4 years in the CIRT group, showing no significant difference (p=0.4). Multivariate analyses showed that treatment choice (SR vs. CIRT) was not identified as a predictive factor for both RFS and OS.

Conclusions: CIRT showed no statistically significant differences in RFS or OS compared with SR, suggesting its potential as a curative treatment option for early-stage HCC.

Abstract Image

查看原文本刊更多论文

碳离子放射治疗的效果相当于肝细胞癌的手术切除。

目的：本研究旨在比较碳离子放疗（CIRT）与手术切除（SR）治疗HCC患者的临床结果。方法：本回顾性研究包括2010年9月和2022年6月在日本机构首次接受CIRT和SR的116和947例患者。我们使用治疗加权逆概率（IPTW）分析来纠正两组患者基线特征的不平衡。结果：SR组的中位观察期为3.3年（IQR: 1.4 ~ 5.8）， CIRT组的中位观察期为2.8年（IQR: 1.6 ~ 4.5）（p=0.2）。IPTW分析前，SR组中位无复发生存期（RFS）为2.3年，CIRT组中位无复发生存期（RFS）为2.2年，差异无统计学意义（p=0.3）。经IPTW分析，SR组的中位RFS为2.5年，CIRT组为2.3年，差异无统计学意义（p=0.9）。SR组未达到中位总生存期（OS），而CIRT组为7.4年。与CIRT组相比，SR组表现出更好的生存率（p=0.02）。在IPTW队列中，SR组的中位总生存期未达到，而CIRT组的中位总生存期为7.4年，无显著差异（p=0.4）。多变量分析显示，治疗选择（SR vs. CIRT）未被确定为RFS和OS的预测因素。结论：与SR相比，CIRT在RFS或OS方面无统计学差异，提示其有潜力作为早期HCC的根治性治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Communications GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

8.00

自引率

2.00%

发文量

248

审稿时长

8 weeks

期刊介绍： Hepatology Communications is a peer-reviewed, online-only, open access journal for fast dissemination of high quality basic, translational, and clinical research in hepatology. Hepatology Communications maintains high standard and rigorous peer review. Because of its open access nature, authors retain the copyright to their works, all articles are immediately available and free to read and share, and it is fully compliant with funder and institutional mandates. The journal is committed to fast publication and author satisfaction.